NHS managers doubt effect of investment hike
This article was originally published in Clinica
Doubts persist among UK NHS managers regarding the levels of investment available to support the ambitious healthcare delivery targets set by the government for 2008. Almost two thirds of NHS chief executives believe that the targets cannot all be met with current funding, according to a survey by the NHS Confederation, presented at its annual conference, last week in Birmingham.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.